Literature DB >> 15630156

Asthma treatment in the 21st century: what's next?

Stephen P Peters1.   

Abstract

Asthma treatment is evolving as we enter the 21st century. This review focuses on several different areas of asthma treatment now in evolution. These include: (1) the proper role of various asthma controllers--either already approved or under investigation--besides inhaled corticosteriods in asthma therapy; (2) the potential role for immune and cytokine modulation for asthma therapy; (3) the potential role for pharmacogenetics in asthma therapy; and (4) whether single-inhaler therapy with a combination of an inhaled corticosteriod and a long-acted beta-agonist could be used for both maintenance and rescue in patients with asthma.

Entities:  

Mesh:

Year:  2004        PMID: 15630156     DOI: 10.1385/CRIAI:27:3:197

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  59 in total

Review 1.  Heterogeneity of therapeutic responses in asthma.

Authors:  J M Drazen; E K Silverman; T H Lee
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.

Authors:  D R Taylor; J M Drazen; G P Herbison; C N Yandava; R J Hancox; G I Town
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

Review 3.  Personalised prescribing for asthma--is pharmacogenetics the answer?

Authors:  Jane C Dewar; Ian P Hall
Journal:  J Pharm Pharmacol       Date:  2003-03       Impact factor: 3.765

Review 4.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

5.  Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma.

Authors:  Eli O Meltzer; Richard F Lockey; Bruce F Friedman; Chris Kalberg; Stacey Goode-Sellers; Sharon Srebro; Lisa Edwards; Kathleen Rickard
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

6.  Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors:  S A Bryan; B J O'Connor; S Matti; M J Leckie; V Kanabar; J Khan; S J Warrington; L Renzetti; A Rames; J A Bock; M J Boyce; T T Hansel; S T Holgate; P J Barnes
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

7.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

8.  Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.

Authors:  J P Kemp; M C Minkwitz; C M Bonuccelli; M S Warren
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

9.  Serious asthma exacerbations in asthmatics treated with high-dose formoterol.

Authors:  Marianne Mann; Badrul Chowdhury; Eugene Sullivan; Richard Nicklas; Raymond Anthracite; Robert J Meyer
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

10.  Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group.

Authors:  A A Verberne; C Frost; E J Duiverman; M H Grol; K F Kerrebijn
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.